Try our beta test site

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

This study has been completed.
Sponsor:
Collaborator:
Premier Research Group plc
Information provided by (Responsible Party):
Octapharma
ClinicalTrials.gov Identifier:
NCT01012323
First received: November 11, 2009
Last updated: February 8, 2017
Last verified: February 2017
  Purpose
The purpose of this study was to determine the efficacy of NewGam in preventing serious bacterial infections and to determine the pharmacokinetic profile of NewGam. The safety of NewGam and its effect on quality of life were also evaluated.

Condition Intervention Phase
Primary Immunodeficiency Diseases
Biological: NewGam
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Clinical Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Patients With Primary Immunodeficiency Diseases

Further study details as provided by Octapharma:

Primary Outcome Measures:
  • Number of Serious Bacterial Infections Per Person-year of Treatment [ Time Frame: Baseline to end of the study (up to 12 months) ]
    The number of serious bacterial infections per person-year of treatment was calculated by the following formula: Total number of serious bacterial infections / patient-years on NewGam treatment. Serious bacterial infections were defined as bacteraemia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess.


Secondary Outcome Measures:
  • IgG Trough Level Concentration [ Time Frame: Baseline to end of the study (up to 12 months) ]
    Total IgG trough concentrations were measured in serum samples taken before each infusion.

  • Trough Level Concentration of Antibodies Against Haemophilus Influenzae [ Time Frame: Baseline to end of the study (up to 12 months) ]
    Trough level concentrations of antibodies against Haemophilus influenzae were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

  • Trough Level Concentration of Antibodies Against Measles [ Time Frame: Baseline to end of the study (up to 12 months) ]
    Trough level concentrations of antibodies against measles were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

  • Trough Level Concentration of Antibodies Against Streptococcus Pneumoniae [ Time Frame: Baseline to end of the study (up to 12 months) ]
    Trough level concentrations of antibodies against Streptococcus pneumoniae (serotypes types 6B, 14, 9V, 18C, 19F, 4, and 23F) were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

  • Trough Level Concentration of Antibodies Against Cytomegalovirus [ Time Frame: Baseline to end of the study (up to 12 months) ]
    Trough level concentrations of antibodies against cytomegalovirus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

  • Trough Level Concentration of Antibodies Against Tetanus [ Time Frame: Baseline to end of the study (up to 12 months) ]
    Trough level concentrations of antibodies against tetanus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

  • Trough Level Concentration of Antibodies Against Varicella-zoster Virus [ Time Frame: Baseline to end of the study (up to 12 months) ]
    Trough level concentrations of antibodies against varicella-zoster virus were measured in serum blood samples collected before the 1st infusion in all participants, before the 9th and 10th infusions in participants receiving NewGam every 3 weeks, before the 7th and 8th infusions in participants receiving NewGam every 4 weeks, and at the termination visit for all participants.

  • Total Number of Infections [ Time Frame: Baseline to end of the study (up to 12 months) ]
    The number of infections included serious bacterial infections (bacterial pneumonia, bacteraemia/sepsis, osteomyelitis/septic arthritis, visceral abscess, bacterial meningitis) and other infections. For other infections, the Medical Dictionary for Regulatory Activities (MedDRA) preferred term was used to determine the type of infection. They were grouped into the following categories as determined by a medical expert: Ear infections, eye infections, infections of the gastrointestinal tract, infections of the genitourinary tract, upper respiratory tract infections, lower respiratory tract infections, infections of the skin, and infections not elsewhere classified.

  • Number of Non-serious Infections [ Time Frame: Baseline to end of the study (up to 12 months) ]
    The MedDRA preferred term was used to determine the type of non-serious infection. They were grouped into the following categories as determined by a medical expert: Ear infections, eye infections, infections of the gastrointestinal tract, infections of the genitourinary tract, upper respiratory tract infections, lower respiratory tract infections, infections of the skin, and infections not elsewhere classified. The total number of infections and the number in each category are reported.

  • Time to Resolution of Serious and Other Infections [ Time Frame: Baseline to end of the study (up to 12 months) ]
    Since infections were reported as adverse events, the time to resolution of an infection was the time from the start date of the infection adverse event to the end date of the infection adverse event.

  • Percentage of Participants Treated With Antibiotics [ Time Frame: Baseline to end of the study (up to 12 months) ]
    The total percentage of participants treated with antibiotics, as well as, the percentage of participants treated with antibiotics therapeutically and prophylactically are reported.

  • Number of Antibiotic Treatment Episodes Per Person-year of Treatment [ Time Frame: Baseline to end of the study (up to 12 months) ]
    The number of antibiotic treatment episodes per person-year of treatment was calculated by the following formula: Total number of antibiotic treatment episodes / patient-years of NewGam treatment.

  • Number of Antibiotic Treatment Days Per Person-year of Treatment [ Time Frame: Baseline to end of the study (up to 12 months) ]
    The number of antibiotic treatment days per person-year of treatment was calculated by the following formula: Total number of antibiotic treatment days / patient-years of NewGam treatment.

  • Number of Participants Hospitalized Due to an Infection [ Time Frame: Baseline to end of the study (up to 12 months) ]
  • Percentage of Participants With at Least 1 Episode of Fever [ Time Frame: Baseline to end of the study (up to 12 months) ]
  • Percentage of Participants That Missed School or Work Due to an Infection [ Time Frame: Baseline to end of the study (up to 12 months) ]
  • Changes in the Physical and Psychosocial Child Health Questionnaire-Parent Form Scores From Baseline to the End of the Study [ Time Frame: Baseline to end of the study (up to 12 months) ]
    The Quality of Life (QoL) questionnaire Child Health Questionnaire-Parent Form (CHQ-PF50) was completed by a parent or guardian in study participants < 14 years of age. The CHQ-PF50 consists of 50 items organized into 15 subscales.The 15 subscales could be combined into 2 summary scores, physical and psychosocial. The calculated summary scores were transformed to a range of 0-100, where a higher score indicates more positive functioning or better health status. A positive change score indicates improvement.

  • Changes in the Physical and Mental Short Form-36 Health Survey Scores From Baseline to the End of the Study [ Time Frame: Baseline to end of the study (up to 12 months) ]
    The Quality of Life (QoL) questionnaire Short Form-36 Health Survey (SF-36-HS) was completed by participants ≥ 14 years of age. The SF-36-HS consists of 36 items organized into 8 subscales. The 8 subscales could be combined into 2 summary scores, physical and mental. The calculated summary scores were transformed to a range of 0-100, where a higher score indicates better health. A positive change score indicates improvement.


Enrollment: 51
Study Start Date: January 2010
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NewGam
Participants received NewGam 200-800 mg/kg intravenously every 3 weeks (17 infusions) or 4 weeks (13 infusions) for 1 year.
Biological: NewGam
The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
Other Name: Human normal immunoglobulin

Detailed Description:
NewGam is a new 10% human normal immunoglobulin (IVIG) solution developed by Octapharma for intravenous administration. It is supplied as a liquid formulation ready to use. The primary therapeutic use of immunoglobulins is to provide antibodies to prevent viral and bacterial diseases (replacement therapy). IVIG has proved to be useful in a variety of clinical conditions other than for replacement of immunoglobulins; IVIG exhibits an immunomodulatory effect. Children and adults with a Primary Immunodeficiency Disease (PID) have an increased risk of recurrent bacterial and viral infections that typically attack the respiratory tract (sinusitis, bronchitis, pneumonia) but can also affect the gastrointestinal tract (gastroenteritis). Theses diseases can be severe and can lead to substantial morbidity. Responses to antibacterial therapy are often poor. At present, most primary immune deficiencies are not curable, but IVIGs have been shown to decrease the total number of severe infections and the duration of hospitalization.
  Eligibility

Ages Eligible for Study:   2 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age of ≥ 2 years and ≤ 75 years.
  • Confirmed diagnosis of common variable immunodeficiency (CVID) or X-linked agammaglobulinemia (XLA).
  • Previously treated with a commercial immune globulin intravenous (human) every 21-28 days for at least 6 infusion intervals at a constant dose between 200 and 800 mg/kg body weight.

Exclusion Criteria:

  • Acute infection requiring intravenous antibiotic treatment within 2 weeks prior to and during the screening period.
  • Exposure to blood or any blood product or derivative, other than commercially available intravenous immunoglobulin (IVIG), within the past 3 months prior to enrollment.
  • Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products, or any component of the investigational product.
  • Requirement of any routine pre-medication for IVIG infusion.
  • Severe liver function impairment (alanine aminotransferase [ALAT] 3x > upper limit of normal).
  • Presence of renal function impairment (creatinine > 120 μmol/L), or predisposition for acute renal failure (eg, any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs).
  • History of autoimmune hemolytic anemia.
  • History of diabetes mellitus.
  • Congestive heart failure New York Heart Association (NYHA) class III or IV.
  • Non-controlled arterial hypertension (systolic blood pressure > 160 mmHg or diastolic blood pressure > 90 mmHg).
  • History of deep vein thrombosis or thrombotic complications of IVIG therapy.
  • A positive result at screening on any of the following viral markers: human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV).
  • Treatment with steroids (oral or parenteral, long-term, ie, 30 days or more, not intermittent or burst, daily, ≥ 0.15 mg of prednisone or equivalent/kg/day), immunosuppressive or immunomodulatory drugs.
  • Planned vaccination during the study period.
  • Treatment with any investigational agent within 3 months prior to enrollment.
  • Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals within the past 12 months prior to enrollment.
  • Pregnant or nursing women.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01012323

Locations
United States, California
Sudir Gupta, MD
Irvine, California, United States
United States, Colorado
Isaac Melamed, MD
Centennial, Colorado, United States
United States, Illinois
James Moy, MD
Chicago, Illinois, United States
United States, Indiana
William Smits, MD
Fort Wayne, Indiana, United States
United States, Missouri
Dr. Alan Knutsen
St. Louis, Missouri, United States, 63104
United States, Nebraska
Ai Lan Kobayashi, MD
Papillion, Nebraska, United States
United States, Washington
Hans Ochs, MD
Seattle, Washington, United States
Sponsors and Collaborators
Octapharma
Premier Research Group plc
  More Information

Responsible Party: Octapharma
ClinicalTrials.gov Identifier: NCT01012323     History of Changes
Other Study ID Numbers: NGAM-01
2009-011434-10 ( EudraCT Number )
Study First Received: November 11, 2009
Results First Received: November 9, 2016
Last Updated: February 8, 2017

Keywords provided by Octapharma:
PID

Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Immune System Diseases
Immunoglobulins
Antibodies
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on March 24, 2017